Clinical trial HOVON 156 AML / AMLSG 28-18
A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy
| Cancers | |
|---|---|
| Organ | Acute leukemia |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Oui |
| Sponsor | Hovon |
| EudraCT Identifier | 2018-000624-33 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04027309 |
| Inclusion criteria | Presence of the FLT3 mutation |
| Last update |